Property | Value |
?:abstract
|
-
Antibodies are becoming a frontline therapy for SARS-CoV-2, but the risk of viral evolutionary escape remains unclear. Here we map how all mutations to SARS-CoV-2’s receptor-binding domain (RBD) affect binding by the antibodies in Regeneron’s REGN-COV2 cocktail and Eli Lilly’s LY-CoV016. These complete maps uncover a single amino-acid mutation that fully escapes the REGN-COV2 cocktail, which consists of two antibodies targeting distinct structural epitopes. The maps also identify viral mutations that are selected in a persistently infected patient treated with REGN-COV2, as well as in lab viral escape selections. Finally, the maps reveal that mutations escaping each individual antibody are already present in circulating SARS-CoV-2 strains. Overall, these complete escape maps enable immediate interpretation of the consequences of mutations observed during viral surveillance.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1101/2020.11.30.405472
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/19920ac9a849ed9691dbc3e7a6c19303d0a3f066.json; document_parses/pdf_json/c0a72dbcb83275823c29158b368039f450c081f1.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
-
BioRxiv; Medline; PMC; WHO
|
?:title
|
-
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
|
?:type
|
|
?:year
|
|